Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
The Global Conductive Inks Market 2024-2035: Conductive Inks are Playing a Pivotal Role in Enabling Next-generation Electronic Devices, Wearables and Energy-efficient Technologies
June 12, 2024 04:30 ET
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Conductive Inks Market 2024-2035" report has been added to ResearchAndMarkets.com's offering. The market for conductive inks is evolving...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
WellSpan Health Partners with Jersey College to Establish a Dedicated School of Nursing in South Central Pennsylvania
June 11, 2024 09:41 ET
|
WellSpan Health
York, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- WellSpan Health and Jersey College, an accredited post-secondary institution specializing in nursing education, have received regulatory approval to...
Clinical ink Appoints Dr. Nicholas Alp, MD PhD FACC as Chief Medical Officer
June 10, 2024 08:00 ET
|
Clinical Ink
Winston Salem, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, announced the appointment of Dr. Nicholas Alp as Chief Medical Officer and EVP, Medical...
Decentralised Clinical Trials market is estimated to grow at a CAGR of 7.6% by 2034: Visiongain
June 06, 2024 12:47 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Decentralised Clinical Trials Market Report 2024-2034: Forecasts by Study Design (Interventional, Observational, Expanded Access), by Indication...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024 08:00 ET
|
Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
United States $1.84 Bn Plastisol Markets, Competition, Forecast and Opportunities, 2029F Featuring Avient, International Coatings Co, Carlisle Plastics Co, Lancer Industries, & Chemionics
May 29, 2024 09:35 ET
|
Research and Markets
Dublin, May 29, 2024 (GLOBE NEWSWIRE) -- The "United States Plastisol Market, By Region, Competition, Forecast and Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's...
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024 17:00 ET
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
May 22, 2024 10:23 ET
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.